BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIM 23A760: Phase II started

Ipsen began an open-label, international Phase II trial in 80 patients to evaluate once-weekly 1, 2, 4 and 6 mg doses of subcutaneous BIM 23A760.

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >